TRTMNT INTRUPTN AMNG SBJTS ON POTENT ANTIRTROVIRAL THRPY W/IN 16 DYS OF DIAGNSS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of this study is to test a vaccine to see if it fights HIV infection. The study vaccine is for people who started anti-HIV drugs soon after they were infected with HIV. We are looking for people who were infected just a few weeks ago (acute infection) or a few months ago (recent infection). The first goal of this study is to see what happens to the amount of HIV in subjects' blood if they receive the study vaccine and then stop taking their anti-HIV drugs. We do not yet know if the study vaccine will make a difference on the amount of HIV in the blood. The second goal of the study is to see if the study vaccine is safe for people who have HIV. If the study vaccine works, people who receive it may be able to take fewer anti-HIV drugs. Vaccines help the body's immune system fight infections such as HIV. People who join this study will receive injections (shots) that contain either the study vaccine or a vaccine placebo. The placebo for this study is a water and salt solution that has no vaccine, medicine, or drugs. We will see if the immune system responds differently in people who receive the study vaccine or the placebo. We will study the immune system by comparing the amount of HIV in the blood (HIV viral load) in people who receive either the vaccine or the placebo and who then stop taking their anti-HIV drugs for 24 weeks, about six months. Many people, but not all, will receive either the study vaccine or placebo as described for this study. Many people on this study, but not all, will be able to stop their anti-HIV drugs for 24 weeks. Those who can both receive the vaccine and stop their anti-HIV drugs will have their viral load measured. The study vaccine or placebo will be given to people by injections (shots) in one upper arm near the shoulder. The placebo is like the study vaccine but without the active material. The study vaccine is called MRKAd5 HIV-1 gag/pol/nef vaccine.